<i>CCR5</i> and <i>CCL5</i> gene expression in colorectal cancer: comprehensive profiling and clinical value.

"Competing interests: H-JL reports receiving honoraria from consultant/advisory board membership for Merck Serono, Bayer, and Genentech. JX, YB, JPA and WMK are employers of Caris Life Sciences. AFS reports funding for research, travel, and the speakers bureau from Caris Life Sciences. BAW reports receiving honoraria from Bayer, Sirtex, Lilly, Taiho, and HalioDx. RMG reports stock and other ownership interests from Advanced Chemotherapy Technologies and Compass Therapeutics, consulting/advisory role for AbbVie, G1 Therapeutics, GSK, Merck, Eisai, Compass Therapeutics, Inspirna, Taiho, Novartis, AstraZeneca, and Bayer, expert testimony from Taiho Pharmaceutical. FI is an AbbVie employee and receives stocks from the company. All remaining authors have declared no conflicts of interest."

"Funding: Research reported in this publication was partly supported by the National Cancer Institute of the National Institutes of Health under Award Numbers U10CA180821 (to the Alliance for Clinical Trials in Oncology), UG1CA233163, UG1CA233373, UG1CA239758 (to BAW), P30CA014089 (to H-JL), U10CA180888 (SWOG), Gloria Borges WunderGlo Foundation, Dhont Family Foundation, Victoria and Philip Wilson Research Fund, San Pedro Peninsula Cancer Guild, Ming Hsieh Research and Daniel Butler Research Fund. Also supported in part by funds from Bristol-Myers Squibb, Genentech, and Pfizer (to the Alliance for Clinical Trials in Oncology). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. Clinical data from Cancer and Leukemia Group B 80405 were obtained directly from the Alliance for Clinical Trials in Oncology, a National Clinical Trials Network cooperative group, under Alliance study A152001. https://acknowledgments.alliancefound.org "